Types of Biotechnology and Their Real Estate Needs

Every biotech company needs two things to operate: the right science and the right space. The science gets most of the attention. The space — and getting it wrong — is what quietly stalls companies at every stage of growth.

The four primary types of biotechnology each have fundamentally different facility requirements. A medical biotech running gene therapy trials needs something entirely different from an industrial biotech scaling up fermentation. What works for one can be operationally useless — or actively non-compliant — for another.

This guide breaks down each type, what the work actually involves, and what the real estate needs to support it.

What Is Biotechnology?

At its core, biotechnology is the use of biological systems, living organisms, or their derivatives to develop products, processes, and technologies that improve human life. The field spans medicine, agriculture, energy, and environmental science — and it’s advancing faster than most industries can track.

What’s less discussed is the infrastructure behind it. Biotech can’t operate out of a standard commercial building. Each branch of the industry has specific facility requirements — lab configurations, mechanical systems, zoning, power capacity, proximity to research institutions — that determine whether a company can actually do its work. Getting the real estate wrong doesn’t just create operational headaches. It can slow clinical timelines, create compliance risk, and make it harder to attract the talent and funding the sector runs on.

The Four Primary Types of Biotechnology

1. Medical Biotechnology

Medical biotechnology is the largest and most capital-intensive branch of the industry. It encompasses drug discovery, biologics development, diagnostics, gene therapy, and vaccine production — essentially any application of biological science to human health outcomes.

Companies in this space range from early-stage startups running first-in-human trials to large pharmaceutical manufacturers operating at commercial scale. The real estate needs vary considerably across that spectrum, but certain requirements are consistent regardless of stage.

Real estate needs:

• Wet labs with BSL-1 and BSL-2 infrastructure — appropriate biosafety level designation, with proper ventilation, waste management, and containment systems built in or readily adaptable
• HVAC systems capable of precise environmental control — temperature, humidity, and air exchange rates that meet GMP or research-grade standards depending on the work being done
• Clinical research facilities with hospital or university proximity — phase I and II trial operations benefit significantly from adjacency to patient populations and institutional research partners
• Flexible lab-to-office ratios — early-stage companies typically need 60–70% lab space with the ability to shift that ratio as they move from research into development
• Loading and cold storage infrastructure — biologics and cell-based therapies require specialized handling from the point of delivery through storage and use

Medical biotech demand remains concentrated in established life sciences clusters — the Bay Area, Boston/Cambridge, San Diego, and increasingly the Research Triangle and Houston. In San Francisco specifically, proximity to UCSF, Stanford, and major hospital systems continues to drive site selection decisions for medical biotech tenants.

With the U.S. biotech industry employing over 2 million people and that figure growing year over year, demand for purpose-built medical biotechnology facilities consistently outpaces available supply in the top-tier markets.

2. Agricultural Biotechnology

Agricultural biotechnology applies genetic science, microbiology, and data-driven breeding to improve crops, livestock, soil health, and food supply chain sustainability. Applications include pest-resistant plant varieties, nitrogen-fixing microbes that reduce fertilizer dependence, and cell-cultured proteins that bypass traditional animal agriculture entirely.

This is a sector undergoing significant investment as climate pressures and food security concerns move up the priority list for governments and venture capital alike. It’s also a sector with real estate needs that look very different from the rest of biotech — less urban cluster, more land and infrastructure-dependent.

Real estate needs:

• Controlled environment agriculture (CEA) facilities — climate-controlled greenhouses and indoor growing systems for crop trials, which require specific light, temperature, irrigation, and CO₂ management infrastructure
• R&D campuses with adjacent or nearby land access — field trials for modified crops require outdoor acreage with appropriate soil conditions and zoning for agricultural research use
• Biosafety containment for GMO research — work involving genetically modified organisms requires specific containment protocols and regulatory compliance, which affects both facility design and location approval
• Cold chain and storage facilities — for biological inputs, seed banks, and sample preservation
• Proximity to agricultural land and regulatory bodies — USDA and EPA oversight means operational sites benefit from location strategy that accounts for regulatory engagement

Agricultural biotech companies are more geographically distributed than other sectors — you’ll find significant activity in the Central Valley of California, the Midwest, and parts of the Southeast where agricultural infrastructure already exists. But R&D operations for companies developing platform technologies often maintain urban or suburban lab facilities alongside field research sites.

3. Industrial Biotechnology

Industrial biotechnology — sometimes called white biotechnology — uses microbial and enzymatic processes to manufacture chemicals, materials, and fuels. Bioplastics, bio-based solvents, specialty enzymes, and next-generation biofuels all fall under this category. As industries push to decarbonize supply chains, industrial biotech has moved from niche to strategically critical.

The real estate profile for industrial biotech is the most operationally demanding of the four primary types. These companies aren’t running bench-scale experiments — they’re operating pilot plants and commercial-scale fermentation facilities that need industrial infrastructure to function.

Real estate needs:

• Pilot plant and manufacturing space with heavy power capacity — fermentation-based operations are energy-intensive; facilities typically need three-phase power, high-amperage service, and backup power infrastructure
• High water capacity and wastewater management — bioprocessing generates significant water usage and organic waste streams that require specialized treatment systems and municipal approvals
• Large floorplate industrial buildings — bioreactor scale-up requires significant floor area and ceiling clearance, often in the 30,000–100,000+ square foot range depending on production stage
• Proximity to ports, rail, or distribution hubs — raw material inputs and finished product distribution favor locations with strong logistics access
• Appropriate industrial zoning — not all industrial zones accommodate the chemical handling and emissions profiles of bioprocessing operations; permitting due diligence is essential

Industrial biotech has been a meaningful driver of demand in secondary and tertiary industrial markets — cities like Houston, Cincinnati, and parts of the Southeast where larger footprints are available at more accessible price points than primary coastal markets. As clean energy mandates tighten and bio-based manufacturing scales, this sector’s real estate footprint is expanding.

4. Environmental Biotechnology

Environmental biotechnology develops solutions develops biological solutions to environmental challenges — bioremediation of contaminated soil and groundwater, biological wastewater treatment, carbon sequestration through engineered organisms, and ecosystem restoration applications. It’s one of the fastest-growing areas of the broader life sciences sector as regulatory pressure and ESG commitments drive demand for non-chemical remediation approaches.

Real estate for environmental biotech sits at the intersection of lab science and field operations — companies in this space often need both bench research capability and the ability to work on-site at contaminated or sensitive environmental locations.

Real estate needs:

• Lab space designed for environmental sample analysis — soil, water, and air sample processing requires specific containment, analytical instrumentation, and waste handling protocols
• Field operation staging areas — bioremediation projects often require on-site equipment storage, mobile lab units, and staging infrastructure near active project sites
• Proximity to industrial zones or brownfield sites — environmental biotech companies frequently work in and around the sites they’re treating, which influences where they locate operational facilities
• Collaboration-ready space — this sector operates in close partnership with municipal governments, environmental agencies, and regulatory bodies, which tends to favor locations with accessible professional infrastructure
• Flexible lease structures — project-based work creates variable space needs over time; environmental biotech tenants often benefit from shorter terms or expansion options that align with project pipeline growth

A Growing Fifth Category: Bioinformatics and Computational Biotechnology

No contemporary overview of biotech types is complete without acknowledging the sector that’s reshaping all of the others. Bioinformatics — the application of computational tools, machine learning, and data science to biological problems — has moved from a supporting discipline to a standalone driver of biotech innovation.

Companies in this space are using AI to accelerate drug discovery, model protein structures, analyze genomic datasets at scale, and identify agricultural breeding targets that would take decades to find through conventional methods. Many of the most well-funded life sciences companies in the Bay Area right now are primarily computational rather than wet lab-based.

Real estate needs:

• Dry lab environments — bioinformatics operations are data and compute-intensive but don’t require wet lab infrastructure. Standard commercial office space with high-density power and cooling for on-premises compute, or proximity to cloud infrastructure, is often sufficient
• High-speed, redundant connectivity — genomic datasets and model training workloads require enterprise-grade internet infrastructure
• Flexible office-to-collaboration ratios — bioinformatics teams tend to be smaller and more cross-functional than traditional bench science teams; open collaborative layouts often work better than fixed lab configurations
• Proximity to life sciences ecosystems — even without wet lab needs, computational biotech companies benefit from being embedded in life sciences clusters where partnerships, talent, and investment flow freely

For landlords and developers, bioinformatics companies represent an increasingly attractive tenant profile — they generate life sciences-caliber rents without requiring the mechanical infrastructure investment that wet lab fit-outs demand.

Frequently Asked Questions

What type of real estate does a biotech company need? It depends on what type of biotechnology the company is working in. Medical and agricultural biotech typically require wet lab space with specialized ventilation, biosafety infrastructure, and flexible lab-to-office ratios. Industrial biotech needs large-footprint manufacturing or pilot plant space with heavy power and water capacity. Environmental biotech often combines lab space with field operation capability. Computational biotech and bioinformatics can operate from standard commercial office space with high-density power and connectivity. No single facility type works across the board — which is why sector-specific real estate expertise matters.

What is the difference between wet lab and dry lab space? A wet lab is a facility designed for experimental work involving liquids, chemicals, biological samples, or live organisms. It requires specialized infrastructure: fume hoods, biosafety cabinets, chemical-resistant surfaces, dedicated ventilation and exhaust systems, and appropriate waste handling. A dry lab, by contrast, is a computational or data-focused environment — it looks more like a conventional office with higher power and cooling demands for servers or workstations. Many modern biotech facilities incorporate both, with wet and dry lab areas designed to work together as research moves from bench science into data analysis.

Which cities have the most biotech real estate? The Bay Area (San Francisco, South San Francisco, and the Peninsula), Boston/Cambridge, and San Diego are the three dominant life sciences real estate markets in the United States, with the deepest talent pools, strongest institutional research ecosystems, and greatest concentration of available lab space. The Research Triangle in North Carolina, Houston, and the New York metro are growing significantly. Los Angeles is an emerging market — particularly in the South Bay and Torrance corridors — with strong medtech and biotech company formation driven in part by the UCLA and USC research ecosystems and the broader Silicon Beach tech cluster.

How is biotech real estate different from standard commercial office space? The differences are significant and affect both construction cost and lease structure. Biotech facilities require mechanical systems — HVAC, plumbing, electrical — that go well beyond standard commercial spec. Wet labs need 100% outside air ventilation systems, higher floor-to-ceiling clearances for equipment, reinforced floors for heavy instrumentation, and specialized utility infrastructure. Build-out costs for lab space typically run two to four times higher than conventional office, which is reflected in higher tenant improvement allowances and longer lease terms. Landlords who invest in life sciences infrastructure generally command a meaningful rent premium over comparable standard commercial product.